Literature DB >> 19330877

Alzheimer's disease: from pathology to therapeutic approaches.

Roland Jakob-Roetne1, Helmut Jacobsen.   

Abstract

Mind how you go: The current strategies for the development of therapies for Alzheimer's disease are very diverse. Particular attention is given to the search for inhibitors (see picture for two examples) of the proteolytic enzyme beta- and gamma-secretase, which inhibits the cleavage of the amyloid precursor proteins into amyloid beta peptides, from which the disease-defining deposits of plaque in the brains of Alzheimer's patients originates.Research on senile dementia and Alzheimer's disease covers an extremely broad range of scientific activities. At the recent international meeting of the Alzheimer's Association (ICAD 2008, Chicago) more than 2200 individual scientific contributions were presented. The aim of this Review is to give an overview of the field and to outline its main areas, starting from behavioral abnormalities and visible pathological findings and then focusing on the molecular details of the pathology. The "amyloid hypothesis" of Alzheimer's disease is given particular attention, since the majority of the ongoing therapeutic approaches are based on its theoretical framework.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19330877     DOI: 10.1002/anie.200802808

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  132 in total

1.  Endocannabinoids prevent β-amyloid-mediated lysosomal destabilization in cultured neurons.

Authors:  Janis Noonan; Riffat Tanveer; Allan Klompas; Aoife Gowran; Joanne McKiernan; Veronica A Campbell
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

2.  The dynamics of Aβ distribution after γ-secretase inhibitor treatment, as determined by experimental and modelling approaches in a wild type rat.

Authors:  Leon M Tai; Helmut Jacobsen; Laurence Ozmen; Alexander Flohr; Roland Jakob-Roetne; Antonello Caruso; Hans-Peter Grimm
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-04-06       Impact factor: 2.745

3.  In silico strategies for the selection of chelating compounds with potential application in metal-promoted neurodegenerative diseases.

Authors:  Cristina Rodríguez-Rodríguez; Albert Rimola; Jorge Alí-Torres; Mariona Sodupe; Pilar González-Duarte
Journal:  J Comput Aided Mol Des       Date:  2011-01       Impact factor: 3.686

4.  Development of bifunctional stilbene derivatives for targeting and modulating metal-amyloid-β species.

Authors:  Joseph J Braymer; Jung-Suk Choi; Alaina S DeToma; Chen Wang; Kisoo Nam; Jeffrey W Kampf; Ayyalusamy Ramamoorthy; Mi Hee Lim
Journal:  Inorg Chem       Date:  2011-09-28       Impact factor: 5.165

Review 5.  Natural products as a source of Alzheimer's drug leads.

Authors:  Philip Williams; Analia Sorribas; Melanie-Jayne R Howes
Journal:  Nat Prod Rep       Date:  2010-11-12       Impact factor: 13.423

6.  Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice.

Authors:  Susanne Aileen Funke; Thomas van Groen; Inga Kadish; Dirk Bartnik; Luitgard Nagel-Steger; Oleksandr Brener; Torsten Sehl; Renu Batra-Safferling; Christine Moriscot; Guy Schoehn; Anselm H C Horn; Andreas Müller-Schiffmann; Carsten Korth; Heinrich Sticht; Dieter Willbold
Journal:  ACS Chem Neurosci       Date:  2010-08-02       Impact factor: 4.418

7.  ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).

Authors:  Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2010-08-18       Impact factor: 4.418

Review 8.  Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Aging Alzheimer's Disease.

Authors:  Thuy Trang Nguyen; Tuong Kha Vo; Giau Van Vo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  A small molecule that displays marked reactivity toward copper- versus zinc-amyloid-β implicated in Alzheimer's disease.

Authors:  Masha G Savelieff; Yuzhong Liu; Russell R P Senthamarai; Kyle J Korshavn; Hyuck Jin Lee; Ayyalusamy Ramamoorthy; Mi Hee Lim
Journal:  Chem Commun (Camb)       Date:  2013-12-10       Impact factor: 6.222

Review 10.  Positron emission tomography radioligands for in vivo imaging of Aβ plaques.

Authors:  N Scott Mason; Chester A Mathis; William E Klunk
Journal:  J Labelled Comp Radiopharm       Date:  2013 Mar-Apr       Impact factor: 1.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.